Repare Therapeutics Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation Canada (Federal Level)
Business Address 7171 FREDERICK BANTING, SAINT-LAURENT, A8, H4S 1Z9
Mailing Address 7171 FREDERICK BANTING, SAINT-LAURENT, A8, H4S 1Z9
Phone (857) 412-7018
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13D/A Beneficial ownership amendment | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 27, 2026 | View on SEC |
| 8-K Current report of material events | January 16, 2026 | View on SEC |
Material Events
8-K Acquisition January 28, 2026
High Impact
- Repare Therapeutics Inc. acquired by XenoTherapeutics, Inc. through its subsidiary Xeno Acquisition Corp.
- Acquisition integrates Repare's innovative synthetic lethality platform and clinical-stage oncology pipeline into XenoTherapeutics.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.